Aika Clinical Trial Platform (Biorce)

Biorce is a Barcelona-based company that builds Aika, a unified clinical trial platform for AI-driven trial design, feasibility and regulatory planning. It serves sponsors and study operators in drug development who need faster protocol design with fewer amendments.

Aika works as an operating system for clinical development with modules for Protocol, Simulation, Feasibility, Contracts and Budgets, Site Activation, Data, Eligibility and Regulatory. It generates trial documents such as protocols, Investigator's Brochures and Informed Consent Forms, with human oversight and private tenant hosting.

• Protocol and Simulation: AI-driven protocol design and simulation.
• Feasibility: trial feasibility assessment.
• Contracts and Budgets: planning of site contracts and budgets.
• Site Activation and Eligibility: operational site and patient criteria workflows.
• Regulatory: regulatory planning with traceable outputs.
• Document generation: protocols, Investigator's Brochures and Informed Consent Forms.

CROs in Vietnam could assess trial feasibility and site selection with AI. Hospital research units could draft protocols and consent forms faster.

• Company-claimed 60% cost reduction and 70% faster clinical development workflow.
• Company-claimed 50% fewer protocol amendments.
• Regulator-ready protocols generated in about 90 seconds (reported).
• Single platform replacing separate planning tools.

Pharma and CROs are adopting AI to shorten clinical development timelines and cut protocol amendments. Vietnam and Southeast Asia are growing as clinical trial destinations, so local CROs and hospital research units may need similar planning tools.

Barcelona, Spain. Series A of USD 52.5M in Feb 2026; earlier funding of about EUR 8.5M including a EUR 3.5M raise in Nov 2024. Data pool reported at over one million clinical trials.